What is Fahr Disease Spectrum (Primary Familial Brain Calcification)?
Fahr disease, now termed Primary Familial Brain Calcification (PFBC), is a rare neurodegenerative disorder characterized by bilateral, symmetrical calcium-hydroxyapatite crystal deposition in the basal ganglia and other brain regions, presenting with a highly variable combination of motor, cognitive, and psychiatric manifestations that can range from asymptomatic to severely disabling. 1
Genetic Basis and Inheritance
PFBC has a confirmed genetic etiology with seven identified causative genes since 2012 1, 2:
Autosomal Dominant Inheritance:
- SLC20A2 (most frequently mutated, accounts for majority of cases)
- PDGFRB
- PDGFB
- XPR1
Autosomal Recessive Inheritance:
- MYORG
- JAM2
- NAA60
The SLC20A2 gene mutations can affect any protein domain, and there is no clear relationship between specific mutations, age of onset, neuroimaging patterns, or clinical severity 2. Approximately one-third of PFBC cases remain asymptomatic despite radiologic calcifications 3.
Clinical Spectrum
Motor Manifestations
The movement disorder spectrum includes:
- Parkinsonism (bradykinesia, rigidity, gait disturbance)
- Dystonia
- Ataxia
- Chorea
- Tremor
- Dysarthria
- Paresis
Neuropsychiatric Manifestations
The psychiatric presentation is remarkably diverse and can be the sole presenting feature, particularly in younger patients 6:
- Cognitive impairment and dementia (frontal-subcortical pattern)
- Depression
- Psychosis (hallucinations, delusions, schizophrenia-like presentations)
- Manic symptoms
- Anxiety disorders
- Personality changes
- Acute psychotic episodes (even in young adults)
Other Clinical Features
- Seizures
- Headache
- Vertigo
- Stroke-like events
- Orthostatic hypotension
Age of Onset and Penetrance
Typical presentation occurs in the fourth to fifth decade of life, though the spectrum extends from childhood to late adulthood 6. Early-onset cases (second decade) with pure psychiatric symptoms have been documented, highlighting incomplete penetrance and variable expressivity 5, 6. The disease demonstrates significant clinical heterogeneity even within families carrying identical mutations 2.
Neuroimaging Characteristics
Computed tomography remains the gold standard for detecting calcifications 7. The characteristic pattern includes:
- Bilateral, symmetrical calcifications primarily in basal ganglia (striatum and pallidum)
- Extension to dentate nucleus, thalamus, cerebral cortex, and subcortical white matter
- Patterns described as spotty, stepping-stone, or serpiginous
- Calcifications typically persist despite metabolic correction
MRI findings include white matter hyperintensities on T2/FLAIR sequences, though CT is superior for calcification detection 8.
Pathophysiology
Three converging mechanisms have been identified 1, 2:
- Dysregulation of inorganic phosphate homeostasis (SLC20A2 and XPR1 genes encode phosphate transporters)
- Impaired endothelial function (PDGFB and PDGFRB genes affect vascular integrity)
- Blood-brain barrier disruption leading to calcium-phosphate precipitation in brain parenchyma
Differential Diagnosis
Critical distinction: PFBC must be differentiated from secondary causes of basal ganglia calcification 10, 9:
Secondary Causes to Exclude:
- Hypoparathyroidism (most common secondary cause)
- Pseudohypoparathyroidism
- Hyperparathyroidism
- Hyperthyroidism
- Chronic kidney disease with mineral-bone disorder (CKD-MBD)
- Glucose metabolism disorders
- Kernicterus
- Cerebrovascular disease
- Demyelinating disease
- Brain trauma
Diagnostic Approach
The diagnostic algorithm should proceed systematically 7:
- Confirm bilateral, symmetrical basal ganglia calcifications on CT
- Obtain metabolic panel: serum calcium, phosphorus, parathyroid hormone, thyroid function, glucose
- Exclude secondary causes before pursuing genetic testing
- Genetic testing with comprehensive next-generation sequencing (whole genome preferred over exome or targeted panels) for patients with:
- Compatible clinical phenotype
- Family history suggestive of inheritance
- No identifiable secondary cause
Management Principles
No disease-modifying treatment currently exists 4. Management focuses on:
Symptomatic Treatment:
- Movement disorders: Standard Parkinson's medications (levodopa, dopamine agonists), anticholinergics for dystonia
- Psychiatric symptoms: Antipsychotics, antidepressants, mood stabilizers as clinically indicated
- Seizures: Anticonvulsants
- Metabolic correction: If secondary causes identified (calcium/phosphate/PTH normalization in hypoparathyroidism or CKD-MBD)
Ongoing Monitoring:
- Multidisciplinary evaluation (neurology, psychiatry, genetics)
- Genetic counseling for affected families
- Regular neurological and psychiatric assessments
- Family screening in confirmed genetic cases
Clinical Pitfalls
The most critical diagnostic error is attributing psychiatric symptoms solely to primary psychiatric disease without neuroimaging 5, 11. Young adults presenting with acute psychosis, personality changes, or cognitive decline warrant brain imaging to exclude PFBC, particularly with movement abnormalities or family history 6.
Radiologic calcifications can precede symptoms by years or decades, and asymptomatic calcifications do not exclude future clinical manifestations 3. Conversely, early metabolic correction in secondary causes may improve neurological outcomes even though calcifications typically persist 9.